Hovda T, Sober S, Padrik P, Kruuv-Kao K, Grindedal EM, Vamre TBA, Eikeland E, Hofvind S, Sahlberg KK(2026) A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score PLoS One, 21(7), e0345431 DOI 10.1371/journal.pone.0345431, PubMed 42418475
Padrik P, Tõnisson N, Hovda T, Sahlberg KK, Hovig E, Costa L, Nogueira da Costa G, Feldman I, Sampaio F, Pajusalu S, Ojamaa K, Kallak K, Tihamäe AT, Roht L, Kahre T, Lepland A, Sõber S, Kruuv-Käo K, Tamm M, Varghese J, Evans DG, AnteNOR and BRIGHT Research Consortia(2025) Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores Cancers (Basel), 17(7) DOI 10.3390/cancers17071056, PubMed 40227593
Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, Lüders T, Fongård M, Nawaz MS, Bosnjak-Olsen T, Buvarp UE, Rosenskiold AKJ, Nguyen NT, Sletbak TT, Seyedzadeh M, Selsås K, Porojnicu AC, Skjerven HK, Hovda T, Sahlberg KK, Torland LA, Lyngra M, Hammarström CL, Hönigsperger EB, Noone JCet al.(2024) The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer Future Oncol, 20(32), 2457-2466 DOI 10.1080/14796694.2024.2377531, PubMed 39073142
